ABSTRACT: Multiple neurotransmitter systems are affected in senile dementia of the Alzheimer's type (SDAT). Among them, acetylcholine has been most studied. It is now well accepted that the activity of the enzyme, choline acetyltransferase (ChAT) is much decreased in various brain regions including the frontal and temporal cortices, hippocampus and nucleus basalis of Meynert (nbm) in SDAT. Cortical M 2 -muscarinic and nicotinic cholinergic receptors are also decreased but only in a certain proportion (30-40%) of SDAT patients. For other systems, it appears that cortical serotonin (5-HT)-type 2 receptor binding sites are decreased in SDAT. This diminution in 5-HT 2 receptors correlates well with the decreased levels of somatostatin-like immunoreactive materials found in the cortex of SDAT patients. Cortical somatostatin receptor binding sites are decreased in about one third of SDAT patients. Finally, neuropeptide Y and neuropeptide Y receptor binding sites are distributed in areas enriched in cholinergic cell bodies and nerve fiber terminals and it would be of interest to determine possible involvement of this peptide in SDAT. Thus, it appears that multi-drug clinical trials should be considered for the treatment of SDAT. RESUME: Deficits au niveau des neurotransmetteurs et des recepteurs dans la demence senile de type Alzheimer. Plusieurs systemes de neurotransmetteurs sont atteints dans la demence de type Alzheimer (DSTA). Parmi eux l'acetylcholine a ete le plus etudie. II est maintenant reconnu que l'activite de l'enzyme choline acetyltransferase (ChAT) est tres diminuee dans differentes regions du cerveau incluant le cortex frontal et temporal, l'hippocampe et le nucleus basalis de Meynert (nbM) dans la DSTA. Les recepteurs cholinergiques muscariniques de type M 2 et nicotiniques du cortex sont egalement diminues, mais seulement chez un certain nombre de patients (30-40%) atteints de DSTA. Pour ce qui est des autres systeme, il semble que les sites de liaison de type 2 pour la serotonine (5-HT 2 ) sont diminues dans le cortex des patients atteints de DSTA. Cette diminution des recepteurs 5-HT 2 est en correlation avec l'abaissement des niveaux de subtances immunoreactives semblables a la somatostatine que Ton trouve dans le cortex des patients atteints de DSTA. Les sites de liaison des recepteurs pour la somatostatine dans le cortex sont diminues chez le tiers des patients atteints de DSTA. Finalement le neuropeptide Y et les sites de liaison des recepteurs pour le neuropeptide Y sont repartis dans des zones riches en corps cellulaires et en terminaisons nerveuses cholinergiques et il serait interessant d'evaluer 1'implication possible de ce peptide dans la DSTA. Ainsi, il semble que des essais theYapeutiques portant sur l'administration simultanee de plusieurs medicaments devraient etre envisages dans le traitement de la DSTA.
Neuropathologically, senile dementia of the Alzheimer type (SDAT) is characterized by higher than normal densities of "senile" plaques and neurofibrillary tangles in various cortical regions, and by marked cell losses in the nucleus basalis of Meynert (nbm).'" 6 The neurochemical identity of these cell bodies projecting to the neocortex has been shown to be mostly cholinergic. 7 "' 3 Interestingly, the presence in cortical plaques and tangles of cholinergic markers' 4 as well as other neurotransmitters and neuropeptides 15 " 20 has been recently demonstrated. However, it remains to be demonstrated if cell losses in the nbm trigger cortical damages or if multiple cortical insults retrogradely affect cell bodies in various subcortical nuclei.
The degeneration of cholinergic cell bodies in the nbm has generated much interest over the last ten years. Various groups have clearly shown that cortical and subcortical cholinergic markers are markedly affected in SDAT, especially in the nbmcortical pathway and hippocampus.
2 ' 5 ' 6 ' 810 ' 2 '" 28 Thus, a great majority of neurochemical studies has focussed on the characterization of cholinergic deficits in SDAT. Similarly, clinical trials in SDAT patients have concentrated, without much success, on using cholinergic-related drugs (for a recent review, see 29 ). However, recent data have clearly demonstrated that other neurotransmitter systems are also affected in SDAT including noradrenaline, 30 "
36 serotonin (5-HT), 53 In this report, we present some evidence demonstrating that cholinergic, serotonergic and somatostatin systems are affected in SDAT. The possible involvement of another peptide, neuropeptide Y, is also discussed.
Brain Cholinergic Markers in SDAT
Numerous markers are available to study cholinergic neurons and the cholinergic synapse. Among them, the enzyme responsible for the acetylation of choline into acetylcholine, choline acetyltransferase (ChAT), has been most studied possibly due to its long post-mortem stability, reliability and ease to assay. 54 Moreover, it is usually assumed that changes in cortical ChAT activity closely reflect the status of the cholinergic synapse and correlate with the severity of SDAT. 6 Multiple studies have clearly demonstrated that ChAT is markedly decreased in cortex (frontal, parietal and temporal), hippocampus and nbm in SDAT patients (early and late on- ). This may indicate that decreased cortical ChAT activity precede and may trigger loss of enzymatic activity in the nbm. On the other hand, it could also be suggestive of defects in the anterograde axonal transport of ChAT in SDAT. 28 In any case, these data clearly demonstrate major losses in the capacity of synthesizing acetylcholine in brain of SDAT patients. 55, 56 Possible alterations in cholinergic receptor binding sites are also of interest from etiological and therapeutic perspectives. Up to date, most studies have concentrated on muscarinic receptor binding sites in SDAT. Early on, major decreases in the total population of muscarinic receptors have been reported. 62 However, most subsequent studies did not confirm this finding and suggested that muscarinic receptor binding sites were not significantly altered in SDAT. 66,67 M, receptors are mostly excitatory, insensitive to N-ethylnaleimide, independent of the presence of cyclic nucleotides and densely located in cortex, hippocampus and striatum. 66, 67 Preferential radioligands include pirenzepine and at low concentrations, quinuclidinyl benzylate (QNB).
58,66,67 M 2 receptor binding sites are generally inhibitory via the blockade of adenylate cyclase, are sensitive to N-ethylnaleimide and found in cholinergic nerves, striatum, cortex, superior colliculus, brainstem, thalamus and various peripheral tissues. 66, 67 Preferential ligands include acetylcholine itself and oxotremorine-M. 59, 66, 67 An example of the distribution of [ 3 H]acetylcholine-M 2 binding sites in human brain is shown in Figure 1 .
Interestingly, it has recently been shown that the density of M 2 muscarinic receptor sub-type is selectively decreased in SDAT. 68 It was also suggested that this decrease was related to the presynaptic localization of M 2 receptor binding sites on cholinergic nerve terminals. 68 We have performed similar experiments and found that between 30-50% of SDAT patients showed significant decreases in the total population of muscarinic receptor binding sites ( of major importance in the etiology of SDAT. Finally, the exact localization of the M 2 receptor sub-type remains to be established. Our results suggest that it is unlikely that all M 2 receptor binding sites are located on cholinergic cell bodies and nerve terminals. We found that the density of cortical M 2 binding sites was decreased in only 30-50% of SDAT patients while cortical ChAT activity was decreased in all cases (Table 1) . Moreover, selective lesions of the nbm-cortical (kainic acid) and septohippocampal (fimbriaectomy) cholinergic pathways did not significantly alter [ 3 H]acetylcholine-M 2 binding in cortical and hippocampal areas in rat brain (Quirion and Richard, unpublished results). Thus, it would appear that M 2 receptors are not exclusively located on cholinergic cell bodies and nerve terminals (presynaptic) in rat and human brain tissues.
Whitehouse et al 60 have just reported that [ 3 H] acetylcholine nicotinic receptor binding sites were markedly decreased in various cortical areas in SDAT. Previous studies were not as conclusive possibly due to the use of inappropriate ligands (a-bungarotoxin). 70JI As shown in Table 1 , we also found that cortical nicotinic receptor binding sites are decreased in a certain proportion of SDAT patients. [ 3 H]nicotine binding was significantly decreased only in patients that had marked alterations in both nbm and cortical ChAT activities (Table 1 ). This could indicate that nicotinic receptor binding sites are preferentially located on cholinergic neurons in brain. 60 Further investigations on nicotinic receptors in SDAT are certainly warranted.
It is also possible to monitor the integrity of the cholinergic nerve terminals by studying the activity of the high-affinity choline uptake (HACU) system located presynaptically. Already, it has been shown that its activity is markedly decreased in the cortex of patients dying from SDAT. , unpublished results) . Thus, it appears that other radiolabelled probes will have to be used to assess the status of the cholinergic presynaptic nerve terminals in SDAT. One of them could be AH-5183, a selective blocker of the vesicular transport of acetylcholine. 7282 [ 3 H]AH-5183 has already been used to characterize these transporter sites in torpedo Californi a 8 2 and rat brain. 83 We are currently studying if it can be used in human brain tissues. If so, it would be of interest to determine if ChAT activity and [
3 H]AH-5183 binding are always affected in similar fashion in SDAT.
Brain Serotonergic Markers in SDAT
Beside the cholinergic system, much evidence has indicated possible involvement of the serotonergic (5-HT) innervation in the etiology of SDAT. Cell losses and the presence of tangles in the raphe nucleus, a region enriched in 5-HT cell bodies, have been reported. 84, 85 Consequently, major decreases in the levels of 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) have been observed in several brain regions including the frontal cortex, insula, cingulate cortex, amygdala, hippocampus and hypothalamus 30,33 -37,42 in SDAT. The specific 5-HT uptake mechanism could also be altered since reduced serotonin uptake 37, 86 and loss of imipramine binding 37 have been reported.
Moreover, 5-HT receptor binding sites are decreased in SDAT, especially the 5-HT 2 receptor sub-type. Marked decreases (up to 50%) in the density of 5-HT 2 binding sites have been found, especially in the hippocampus, frontal and temporal cortices. 35, 36, 38 '" In our study, we observed marked losses in 5-HT 2 binding sites in the temporal cortex of patients dying from SDAT (Table 2) . Thus, unlike the various cholinergic receptor sub-types, 5-HT 2 receptors seem to be decreased in the brain of all SDAT patients. Interestingly, there is also some evidence that alterations in 5-HT 2 binding sites are more pronounced in the early onset-type of SDAT 35 and it is possible that the decrease in 5-HT 2 binding sites could be related to the localization of these sites on cholinergic nerve terminals in the nbm-cortex pathway. 81 Other 5-HT receptor sub-types of the 5-HT, group (5-HTi A , 5-HT, B , 5-HT, c ) are possibly slightly decreased in SDAT. 37 However, a recent study has not been able to confirm this finding. 36 In summary, it seems clear that 5-HT, its metabolites and especially 5-HT 2 receptor sub-types are decreased in SDAT. For ChAT activity, data represent means ± S.E.M. of 3-6 determinations. 28 Binding data are derived from full saturation analysis and represent maximal binding capacity (B max ). All clinical and neuropathological data have been reported before. 28 ChAT activity has been determined by Fonnum. 54 ['H] ketanserin binding has been performed as described before. 81 ChAT activity is added for comparison.
Thus, therapeutic approaches using 5-HT related drugs alone or in combination with other (cholinergic) drugs should be carefully considered;
Somatostatin in SDAT
Among the various neuropeptides studied for possible alterations of their levels in SDAT, somatostatin (SS) is certainly the only one that consistently showed marked decreases. Various reports have clearly demonstrated that SS levels are much decreased in SDAT, especially in the temporal and frontal cortices, hippocampus and cerebrospinal fluid. 44 " 51 We have also obtained similar data in our series of SDAT patients (Table  3) . Interestingly, the decrease in SS-like immunoreactivity correlates well with 5-HT 2 receptor losses 35 suggesting possible association between these two "markers" in cortical brain regions.
A recent report has also suggested that SS receptor binding sites could be markedly decreased in cortical areas in SDAT. 51 However, our data suggest that SS receptor binding sites are diminished only in a certain proportion of SDAT patients (Table  3) and further studies will be necessary to more precisely determine the exact status of SS receptors in SDAT.
In any case, it already suggests that somatostatin (or analogues) replacement therapies should be considered, at least for the sub-population of SDAT patients in which SS receptors are not altered. In that regard, the recent demonstration that SS delays extinction and reverses electroconvulsive shock-induced amnesia in rats is of great interest. 88 
Neuropeptide Y in SDAT
Neuropeptide Y (NPY) is one of the most highly concentrated peptides in the brain. 
Control
For ChAT activity, data represent means ± S.E.M. at 3-6 determinations. 28 Binding data are derived from full saturation analysis and represent maximal binding capacity (B mnx ). All clinical and neuropathological data have been reported before. 28 ChAT activity has been determined as described by Fonnum. 54 but we have recently described the autoradiographic distribution of NPY binding sites in rat brain. 95 High densities of sites are present in cortex, hippocampus, thalamus and septum ( Figure  3) . Thus, high levels of NPY and NPY receptor binding sites are found in brain regions enriched with cholinergic innervation.
Only limited data have been reported on NPY-like immunoreactivity in SDAT patients. 96 " 98 Thus far, decreased levels, 98 modified laminar distribution 97 or normal levels 9196 in NPYlike peptides have been found in cortex of SDAT patients. The presence of NPY-like immunoreactivity in neuritic plaques has also been demonstrated. 18 Studies on NPY receptor binding sites in SDAT brains have yet to be reported. Clearly, investigations on NPY and NPY receptors in SDAT are of interest, especially since this peptide is often co-localized with SS and its receptors are present in areas enriched with cholinergic innervation.
CONCLUSIONS AND PERSPECTIVES
In summary, multiple neurotransmitter systems are affected in SDAT. The cholinergic innervation is certainly much decreased, especially in the nbm, temporal cortex and hippocampus. Of the various markers used to monitor the cholinergic synapse, it was found that cortical ChAT activity is much decreased in SDAT. The high affinity choline uptake and the acetylcholine storage system are also most likely decreased in all cases. In terms of receptors, it seems that cortical muscarinic-M2 receptors and nicotinic receptors are significantly decreased in a sub-population of SDAT patients. M| receptors are not affected. Thus, clinical treatments with cholinergic drugs could potentially be beneficial if they can reach remaining brain receptor sites. The intraventricular bethanechol infusions precisely attempt to examine this issue.
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The serotonergic system is also affected in SDAT. Lower than normal levels of 5-HT and 5-HIAA are found in various cortical brain regions in certain patients while 5-HT 2 receptors are markedly decreased in most, if not all, SDAT cases. Thus replacement therapies with potent 5-HT 2 -related drugs should be considered possibly in combination with cholinergic drugs. This could be most relevant especially since it has been recently shown that the combination of cholinergic and serotonergic agonists was more effective than either drug alone in restoring learning deficits in animals.
Somatostatin-like immunoreactivity is certainly much decreased in various cortical regions of brain SDAT patients while its receptors could be diminished in a certain percentage of SDAT patients. Thus, clinical trials with stable SS analogues should be planned, either in combination with other treatments (with cholinergic and/or 5-HT drugs) or alone. In any case, it appears that intracerebroventricular infusions will be the best approach, at least until the discovery of stable SS analogues capable of rapidly crossing the blood-brain barrier.
Finally, other neurotransmitter systems such as glutamate and catecholamines are most likely affected, at least in a certain proportion of SDAT patients. This markedly complicates the design of useful treatments of the disease and suggests multidrug clinical trials. However, this will most likely generate a variety of side-effects that will be difficult to control. Thus, we believe that more global approaches would have to be envisioned in the future. For example, we are now focussing on the characterization of more general and basic deficits in the brain of SDAT patients, including possible alterations in protein translocation, 101 calcium mobilization 102 and neurotrophic factors. 103 We hope that it will be possible to develop more appropriate therapies based on drugs modulating these biochemical events.
